2015
DOI: 10.1111/tri.12586
|View full text |Cite
|
Sign up to set email alerts
|

Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice

Abstract: SummaryThere is notable heterogeneity in the implementation of cytomegalovirus (CMV) prevention practices among CMV-seropositive (R+) kidney transplant (KT) recipients. In this prospective observational study, we included 387 CMV R+ KT recipients from 25 Spanish centers. Prevention strategies (antiviral prophylaxis or preemptive therapy) were applied according to institutional protocols at each site. The impact on the 12-month incidence of CMV disease was assessed by Cox regression. Asymptomatic CMV infection,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
24
2
1

Year Published

2015
2015
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 30 publications
(28 citation statements)
references
References 44 publications
1
24
2
1
Order By: Relevance
“…While our study involved DϩRϪ kidney transplant recipients who are at the highest risk for CMV infection and disease (11,23), we acknowledge that we did not evaluate the use of RG7667 in DϩRϩ patients who comprise the majority of kidney transplant recipients (39,40) and who are at risk for superinfection by CMV from a CMVseropositive donor, particularly in the setting of intense immunosuppression (40). Further study of the utility of RG7667 in a broader population of kidney transplant recipients who may suffer from CMV-related consequences would be of clinical interest.…”
Section: Discussionmentioning
confidence: 99%
“…While our study involved DϩRϪ kidney transplant recipients who are at the highest risk for CMV infection and disease (11,23), we acknowledge that we did not evaluate the use of RG7667 in DϩRϩ patients who comprise the majority of kidney transplant recipients (39,40) and who are at risk for superinfection by CMV from a CMVseropositive donor, particularly in the setting of intense immunosuppression (40). Further study of the utility of RG7667 in a broader population of kidney transplant recipients who may suffer from CMV-related consequences would be of clinical interest.…”
Section: Discussionmentioning
confidence: 99%
“…CMV prevention can be attempted using antiviral prophylaxis (administration before any evidence of infection) or preemptive treatment (administration based on laboratory evidence of active but asymptomatic infection) . Although these approaches appear to result in similar incidences of CMV infection and disease, E‐CMV disease usually occurs with preemptive anti‐CMV therapy, while in contrast L‐CMV disease is often observed following prophylactic anti‐CMV therapy (administered most frequently in high‐risk D+/R− patients), or after the development of resistance to antiviral treatment . Clinical trial data can provide insight into the changing patterns of CMV disease and its impact on clinical outcomes, but can also have limitations.…”
Section: Introductionmentioning
confidence: 99%
“…Clinical trial data can provide insight into the changing patterns of CMV disease and its impact on clinical outcomes, but can also have limitations. Data from large registries or databases, however, have the potential to provide additional information in order to determine CMV disease burden among patients who underwent an SOT …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…La infección aguda por citomegalovirus (CMV) en el paciente post trasplante renal, se ha relacionado con un efecto citopático en las células epiteliales glomerulares y tubulares, con alteración de las moléculas de adhesión e inflamación resultando en nefritis intersticial; explicando la menor supervivencia del injerto a largo plazo 12 ; se ha demostrado que un esquema de profilaxis anti-viral en los pacientes seronegativos reduce la incidencia de esta infección en el postrasplante y el riesgo de pérdida del injerto 13 ; en el presente estudió, se presentaron limitaciones en el tamaño de muestra para explorar asociaciones por subgrupo, impidiendo establecer la asociación del CMV con la pérdida del injerto.…”
Section: Discussionunclassified